Welcome to our dedicated page for GLAUKOS SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corporation reported record second-quarter 2026 net sales of $185.6 million, up 50% year over year on a reported basis, driven primarily by growing adoption of iDose TR and early Epioxa contributions. Glaucoma revenue reached $155.2 million, including U.S. glaucoma of $118.5 million, while Corneal Health delivered $30.4 million, including about $11 million from Epioxa. GAAP gross margin was approximately 82% and non-GAAP gross margin about 85%. The company remained loss-making, with GAAP net loss of $18.4 million and non-GAAP net loss of $8.3 million, both narrower than the prior year.
Selling, general and administrative expenses rose to $116.1 million (non-GAAP $111.7 million) and R&D to $51.3 million as Glaukos invested in commercialization and its pipeline, including a $1.5 million acquired in-process R&D charge. The company ended the quarter with about $289.3 million in cash, short-term investments and restricted cash and no debt. Reflecting strong momentum, Glaukos raised its 2026 net sales outlook to $680–$700 million, up from $620–$635 million, supported by iDose TR, Epioxa and broader interventional glaucoma initiatives.
GLAUKOS Corp SVP & Chief Financial Officer Alex R. Thurman exercised options for 10,000 shares of common stock at an exercise price of $38.68 per share on July 16, 2026, then sold 10,000 shares at $160.00 per share. The option exercises and sales were effected under a Rule 10b5-1 trading plan adopted on December 15, 2025. Equity holdings also include 5,230 unvested restricted stock units and 225 shares acquired through the Employee Stock Purchase Plan.
Alex R. Thurman filed a notice to sell 10,000 shares of Glaukos common stock. The shares are planned to be sold on the NYSE through Fidelity Brokerage, with a stated value of $1,600,000.00. They were acquired via a cash stock option exercise dated July 16, 2026. Over the prior three months, Thurman reported three separate 10,000-share sales of Glaukos common stock, with transaction values of $1,400,000.00, $1,500,000.00 and $1,550,000.00.
Glaukos Corp SVP & Chief Financial Officer Alex R. Thurman exercised stock options for 10,000 shares of Common Stock at $38.68 per share and, on the same date, sold 10,000 shares at $155.00 per share in an open-market transaction, all under a Rule 10b5-1 trading plan.
After these transactions, he holds 43,681 shares directly, including 5,230 restricted stock units that have not yet vested or been delivered, and 10,000 stock options with a $38.68 exercise price expiring on October 6, 2026, which vest over four years from the grant date.
Glaukos Corporation notice reports an intended sale of 10,000 shares of Common Stock on 07/09/2026 by Fidelity Brokerage Services LLC, reflecting a reported aggregate value of $1,550,000.00. The filing also records a stock option exercise tied to the same 10,000 shares with cash consideration on 07/09/2026.
The excerpt lists prior Rule 144 dispositions by Alex R. Thurman: 10,000 shares on 04/30/2026 for $1,400,000.00 and 10,000 shares on 07/06/2026 for $1,500,000.00. Shares outstanding are shown as 58,733,911 as of 07/09/2026.
Glaukos Corp SVP & Chief Financial Officer Alex R. Thurman reported an exercise-and-sale transaction in company stock. On July 6, 2026, he exercised stock options for 10,000 shares of common stock at $38.68 per share and, on the same date, sold 10,000 shares of common stock in an open-market transaction at $150.00 per share. After these transactions, he directly holds 43,681 shares of Glaukos common stock, in addition to 5,230 restricted stock units that are unvested. Both the sale and the option exercise were carried out under a Rule 10b5-1 trading plan adopted on December 15, 2025, indicating they were pre-arranged rather than opportunistic market trades.
Glaukos Corp chief development officer Tomas Navratil reported a small open-market sale of company stock. On July 1, he sold 716 shares of Glaukos common stock at an average price of $139.06 per share in an open-market transaction.
After the sale, Navratil directly holds 87,634 shares of Glaukos common stock, so the transaction represents a minor portion of his overall stake. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, indicating it was scheduled in advance. His holdings also include 38,817 restricted stock units that have not yet vested or been delivered.
Glaukos Corp. disclosure shows a reported sale transaction involving 10,000 shares of Common Stock tied to a Stock Option Exercise. The filing lists a broker/dealer Fidelity Brokerage Services LLC and dates including 04/30/2026 for a past sale and 07/06/2026 as a securities-to-be-sold date.
GKOS reported Form 144 notice related to Common Stock transactions by Tomas Navratil. The filing shows sales of $246,177.94 for 2,093 shares on 04/10/2026 and $200,855.16 for 1,537 shares on 06/16/2026. The record also lists 716 shares issued on 03/24/2025 from Restricted Stock Vesting for compensation.
Glaukos Corp chairman and CEO Thomas William Burns reported updated holdings of the company’s common stock, mainly through several family and charitable trusts. The filing lists indirect positions including 100,000 shares through the Janet M. Burns Irrevocable Trust and 1,141,593 shares through the Burns Family Trust.
The only actual share movement was a tax-withholding disposition of 4,059 directly held shares at $142.57 per share to satisfy tax obligations upon vesting and delivery of restricted stock units granted on March 18, 2021. After this, he directly holds 68,967 shares, and his position also includes 56,382 restricted stock units that have not yet vested or been delivered.